Last reviewed · How we verify

NCT06060197

MCT8 Deficiency Caregiver Study

Completed Last updated 25 April 2024
What this trial tests

trial in Monocarboxylate Transporter 8 (MCT8) Deficiency in 21 participants. Completed in 12 April 2024.

Timeline
23 August 2022
Primary endpoint
12 April 2024
12 April 2024

Quick facts

Lead sponsorRare Thyroid Therapeutics International AB
StatusCompleted
Study typeOBSERVATIONAL
Enrollment21
Start date23 August 2022
Primary completion12 April 2024
Estimated completion12 April 2024
Sites1 location across United Kingdom

Conditions studied

Sponsor

Rare Thyroid Therapeutics International AB

Who can join

18 and older, any sex, with Monocarboxylate Transporter 8 (MCT8) Deficiency or Allan-Herndon-Dudley Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Caregivers face many responsibilities outside of their role as a friend or parent, which can lead to emotional, financial, social, and professional challenges. To better understand the impact of MCT8 deficiency on caregivers, Egetis Therapeutics are conducting an online survey for adult caregivers of persons living with the MCT8 deficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Rare Thyroid Therapeutics International AB trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06060197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing